Global Botanical
and Plant Derived Drugs Market, by Source (Plant, Algae, Macroscopic fungi,
and Others), by Dosage Form (Pills, Tablets, Capsules, and Injection), By
Therapeutic Application (Central Nervous System, Cardiovascular Diseases,
Infectious Diseases, and Respiratory Diseases), By Region (North America,
Europe, Latin America, Middle East, Asia Pacific, and Africa) is estimated to
be valued at US$ 30.1 billion in 2017 and is projected to exhibit a CAGR of
6.3% over the forecast period (2017 - 2025).
High risk of side-effects due to
consumption of synthetic drugs such as allergic reaction and gastrointestinal
upsets, drug recalls, and high cost of specialty drugs are propelling demand
for botanical and plant derived drugs. Furthermore, legalization of medicinal
cannabis in several countries have made the manufacturers to invest in the
research and development to derive drugs for cannabis. For instance, one of the
drug by GW Pharmaceuticals, Epidiolex drug consists of cannabidivarin (CBDV) is
in developmental process, which will be used in clinical trials for treatment
resistant epilepsy, supported by NSW and Queensland government in 2016.
Moreover, Insys Therapeutics, an America-based company have Subsys drug in
their product portfolio, which is prescribed for the treatment of advanced pain
associated with cancer. The subsys is a synthetic version of cannabidiol (CBD)
and has accounted for almost 100% of the company’s 2014 year-to-date revenue.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1737
Browse 35 Market Data Tables and
41 Figures spread through 179 Pages and in-depth TOC on "Botanical and
Plant Derived Drugs Market, by Source (Plant, Algae, Macroscopic fungi, and
Others), by Dosage Form (Pills, Tablets, Capsules, and Injection), by
Therapeutic Application (Central Nervous System, Cardiovascular Diseases,
Infectious Diseases, and Respiratory Diseases), by Region (North America,
Europe, Latin America, Middle East, Asia Pacific, Africa) - Global Forecast to
2026"
Increasing applications of
botanical and plant derived drugs are receiving regulatory approvals with
respect to cancer patients - as a cure and as a supplement to current
treatments, which provides a great opportunity for conducting clinical trials.
For instance, in June 2017, Medlab Clinical received approval to begin human
trials of two different cannabis based medicines – NanaBis and NanaBidial.
NanaBis is packaged as a mouth spray and will be clinically tested in advanced
stage for cancer patients with intractable pain. NanaBidial comprises
cannabidiol derived from marijuana and is indicated for chemotherapy induced
nausea and vomiting, with a secondary endpoint in patients suffering seizures
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/botanical-and-plant-derived-drugs-market-1737
Key takeaways of the Botanical
and Plant Derived Drugs Market:
The global botanical and plant
derived drugs market is expected to expand at a CAGR of 6.3% during the
forecast period (2018 – 2026), owing to increasing adoption of herbal drugs
over the synthetic drugs.
Among source type, plant segment
is expected to hold a major market share over the forecast period, owing to
increasing number of clinical trials for medicinal cannabis.
Furthermore, Asia Pacific is
expected to show the most lucrative CAGR in the botanical and plant derived
drugs market, owing to entry of local players and key players, which are
engaged in development of herbal medicines.
Some of the major players
operating in global botanical and plant derived drugs market include Bayer
Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals,
Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, and GW
Pharmaceuticals.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1737
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment